thanks for of you, CABs the proprietary earnings addressing us joining needs therapies for and leader the biologics conditionally attacking avoiding development call. using cells selectivity fourth while Bruce, full Thank XXXX active thereby to a platform unmet with quarter for BioAtla BioAtla in is novel inventor oncology in healthy lives. cells, year everyone and patients' critical to our improved tumor improve or
BAXXXX, in clinical product progress XXXX considerable made CAB-ADC the our trials including Phase candidates, We BAXXXX of targeting programs, and II first-in-class solid all multiple tumor ongoing for our types. across
antibody cell IO CAB CTLA-X CAB EpCAM T bispecific Our and dual our first engager. CDX
second We year. the our focused prioritized trajectory of generating in enable into or us data to more XXXX, one that registrational advancing further trials positive on sets potentially continue into programs CAB move the the half
We market or strategic points believe with the maximize and this these development their collaborations assets near-term accelerate that also of more major inflection support formation year, selected the opportunities. of partners can which one pharmaceutical
company in to website. presentation, I'm are Additional press details our provide and of related updated our which are both what release available going on available to today's
refractory review now commercial tumor our sizable opportunity. which will a of and need across unmet areas represents beginning antibody CAB-CTLA-X with both applicable multiple is I BAXXXX in latest indications, updates, high for patients for our solid first-line and
to of II immune-related data terms in Phase at We dose adverse dose escalation are milligrams our report incidence and to pleased mirror continues XXX I that events. flat severity Phase our low of data
levels of dose including the and improved studies is X in survival demonstrated higher are to cancers, now unprecedented report have inhibition. In previous cleared X gram I'm level. XXX of dose a happy CTLA-X for that the first metastatic we higher milligrams, important tocilizumab overall evaluating This addition, with since melanoma, with cycles
in As patients we cell are PD-X readouts significant enrolling cancer and targeted first-line a population patients first-line non-small with in lung a this XXX result, year. in milligrams combination at melanoma now for later
for the half also of one more or in are to indications the company second in potentially data first-line These trials this registrational anticipated position year.
as part II XX in BAXXXX In in with data of of evaluation of melanoma addition, refractory tolerability treatment our completing are and an the initial quarter. safety second the readout we patients and carcinoma Phase of expansion approximately and
confirmed dose. at our remaining XXX-milligram that combined and to believe dose. be a out a be of as expand noted, complete and efficacy response Phase holds confirmed the the the for patients potential immune demonstrating are study the and data we now often a safety X where And is the as using to can from patients enrolling has the already BAXXXX As With promise inhibitor CTLA-X we the evolving indications the used data, inhibition XXX-milligram PD-X partial potentially be I clinical effective. both checkpoint X best-in-class response encouraging
synergistic that safety control. PD-X BAXXXX tumor be suitable therapies modulation with further and/or suggests AXL the to addition, profile with RORX In emerging achieve durable target for immune CAB-ADC combining may that
turning to CAB-RORX-ADC our Now asset BAXXXX.
head trials agnostic melanoma patient reported neck For Phase populations, previously the treatment responses encouraging our studies. refractory squamous ongoing of carcinoma we II cell RORX and Phase and in the in II
line with QX anticipate melanoma and neck scans for neck anticipated call readouts in the earnings head scans regimen and XX dosed milligram XX and head month patients.
We XQXW X-plus And the of X-plus kilogram in have total XX today's May. update, patients head intense top neck both the during patients per and for X.X in and in using we next the our neck a head data regimen. QXW dosed cohort having more both using As of XX cohort and part melanoma now patients May
the encouraging the Given across global multiple of tumor we data positioned this emerging strategic indications. well believe BAXXXX potential is solid a maximize sets, collaboration to for CAB-ADC
CAB-AXL-ADC our BAXXXX. to On
manageable XX XQXW next of agnostic with at remaining potentially potentially the pleomorphic multiple having this encouraging We milligram across kilogram enrollment registrational group, or to II sarcoma, the with the Phase potentially for patients study to scans compliance approximately Our in enabling AXL study anticipate of of meeting track the patient portion month on year. regimen a and X.X second discuss is complete registrational half undifferentiated the FDA UPS, safety. per the
We meaningful and with treatment tissue refractory sarcomas, new antitumor patients profound among treatment also activity which bone reported clinically unmet a soft for need tractable options. and remain
of earlier treated QXW. The disease observed BAXXXX mate signals at from osteosarcoma monotherapy to a disease control with and X ESMO with patients represents was report. oral We Phase treatment-refractory for tolerated data presented control month, using associated promising cancers XX the this showed patients the profile out safety regimen these no milligram at less sarcomas. the this In per an a XX% XX Part enrollment with and as cohort II X responses for sarcoma efficacy meeting XX rare weeks We presentation manageable the safety well X.X patients. treatment of partial believe of new evaluable kilogram cohort, we intense with
lung Now population. safety II last with in clinical multiple non-small cancer durable reported AXL-positive we a refractory cell regarding Phase quarter, lung cancer, our treatment challenging differentiated profile study responses among a
believe X.X duration per had observed EGFR of X Specifically, patients we using was groups meaningful one AXL-positive in milligrams every received tumors such median poor responses Toxicity few dosing. multiple kilogram X clinically a treatment, responses PD-X months and who a and is prognostic treatment-emergent with response reported. high-grade partial wild-type week QXW other among this as of We approximately with prior manageable treatment-refractory were related relevant. AEs XX
of since prior X these patients have lines a failure therapy. of Particularly experienced median of
and patients XX enrolled of today's both squamous X.X we target-agnostic intense XQXW update, part using kilogram have As milligram patients. non-squamous per the regimen across more
We agnostic population the lung clinical year. track evaluate non-small are second benefit in the of in to quarter this on cancer, target cell nonsquamous
the potentially cancer cell CAB-EpCAM, engager bispecific BAXXXX. or is the T achieve on CAB surface Next, from optimal technology and first-in-class which antibody, ubiquitous to CAB-CDX cells, a use of of our CAB dual selectivity CAB our safety. target expressed EpCAM requires to
I/II year. potential half study with initiation readout Phase of Phase on second is to full I second Phase II the in this study half a and dose a We also the Our in of of study completion this escalation of anticipated continues the data year with anticipate track. progress
T enrolled, wide enabled of the cancers and patients a range of shown among cancer treat If has with to potential colon, others. CAB among including to tumors, patients be prostate effective metastatic safe engager cell and lung, our pancreas breast,
next-gen ADCs discussed, release, previously reduce carbohydrate the and we a have modality yielding toxicity BAXXXX. with system stability, superior across linker glyco conjugate CAB-NectinX-ADC multiple with payload a serum developed we promising off-target applicability tumor-specific broad with novel to types are associated neutropenia from As solubility first our treatment potential further tumor risk
analog vedotin regression in AACR meeting and presented, in cancer demonstrating be pancreatic compared April, upcoming patient-derived Including efficacy to the data superior models. enfortumab efficacy xenograft tumor At the model. will complete
as quarter report models. medical These data our conferences reduced AACR annual and present Rick found turn would I and IND indicate cancer finally, scientific communities primates also like in PK the and progress call to to Rick? both and and pleased more is our linker with year ESMO toxicity. numerous Rare effective financials. of be such will well influence April.
And on I over the publications communications our as which submit toxicology We a presentations, as nonhuman review plan that, including CAB-NectinX-ADC specific technology We full the meeting NextGen treatment the website.
With April, and fourth in to CAB and the and SITC our potentially with Sarcoma at that data important with Cancers, ongoing am to Spring can now to in XXXX the
